Status:
UNKNOWN
Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
Lead Sponsor:
Konkuk University Medical Center
Conditions:
Alzheimer's Disease
Dementia
Eligibility:
All Genders
50-90 years
Phase:
PHASE4
Brief Summary
This study will evaluate the pharmacological efficacy on language capability and compliance with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients with probable A...
Eligibility Criteria
Inclusion
- probable Alzheimer's disease in accordance with NINCDS-ADRDA criteria
- MMSE score equal to or less than 20
- Brain CT or MRI scan performed within the past 12 months
- living or having regular visit at least three times a week from caregiver
- able to visit outpatient clinic and to perform cognitive function test
- already taking stable dose of donepezil for 3 months prior to screening
- subject and caregiver who signed informed consent
Exclusion
- involved in another clinical trial within 4 weeks prior to screening
- severe or unstable disease: acute or severe asthma, unstable or severe cardiovascular disease, acute peptic ulcer,chronic renal failure
- bradycardia (pulse rate less than 50bpm), sick sinus syndrome
- any laboratory finding including cognitive impairments(vitamine B12 or folic acid, syphilis, thyroid disease)
- severe auditory or visual disturbance
- other degenerative disease or psychosis
- taken any drug used for the treatment of Alzheimer's disease or dementia
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2015
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT01849042
Start Date
January 1 2013
End Date
August 1 2015
Last Update
August 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Konkuk university medical center
Seoul, South Korea, 143-729